



CHIMERIC THERAPEUTICS

20  
26

# CHIMERIC

PIONEERS IN CELL THERAPY

NWR 2026



ASX:  
CHM



## DISCLAIMER

Certain statements contained in this presentation, including, without limitation, statements containing the words “believes,” “plans,” “expects,” “anticipates,” and words of similar import, constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Chimeric (collectively, “Chimeric” or the “Company”) to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favourable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided






prior to their approval of our products.

Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This presentation may not contain all the details and information necessary for you to make a decision or evaluation. Neither this presentation nor any of its contents may be used for any other purpose without the prior written consent of the Company.



# INVESTMENT OVERVIEW

-  **3 Phase 1 clinical trials**  
under 3 FDA INDs at 6 leading US centres
-  **Multiple clinical updates**  
in the next 6mths
-  **Experienced leadership team**  
in cell therapy clinical development
-  **CHM-CDH17**  
the FIRST CDH17 CAR-T in clinical trials
-  **Robust and long life**  
patent portfolio

## CORPORATE PROFILE

Exchange	ASX: CHM
Share Price	\$0.002
52 Week Range	\$0.001 - 0.009
Market Cap	~ 8.8m
Shares on issue	~3.6B
IPO 2021	




# CHM: FOCUSED PORTFOLIO

2 Novel cell therapies; 3 Clinical Trials

CHM CDH17  
CAR-T

Technology from:



PHASE 1/2 TRIAL OPEN  
4 sites active

CHM CORE-NK  
'OFF THE SHELF' NK

Technology from:



PHASE 1B TRIAL OPEN MD Anderson	PHASE 1B TRIAL SUSPENDED Case Western
---------------------------------------	---



# CHM CDH17


Clinical Trial Update






# ENCOURAGING PRE-CLINICAL RESULTS


CDH17 CAR T induced complete eradication of tumours with no relapse in seven mouse models




### NEUROENDOCRINE TUMOURS



### GASTRIC CANCER



### PANCREATIC CANCER



CHM CDH17  
CAR-T



Source: Feng et al., Nature Cancer, 2022




# CHM CDH17 CAR-T PHASE 1 RECRUITING

The first CDH17 CAR T cell therapy in clinical trials globally



Technology from:



## PERSONALISED CAR-T: AUTOLOGOUS

4 sites actively recruiting: Sarah Cannon, UPenn, UChicago, Emory

FDA IND November 2023

First Patient Dosed August 2024

FASTRACK Designation April 2025: Neuroendocrine Tumours

ORPHAN Designation December 2025: Gastric Cancer

Manufacturing: 12/12 successful runs; GMP Compliant


12 Patients enrolled:

11 Patients treated, 1 awaiting dosing

N= up to 15 patients



# Phase 1/2 Clinical Trial of CHM CDH17



NCT06055439





# CHM CDH17 PROGRESS AS AT MARCH 23, 2026

Dose Level	Status	Notes
1 50m	Completed	4 patients treated 1 patient remains on study
2 150m	Recruitment completed	5 patients treated – all achieved SD at Day 28 1 awaiting treatment
3 450m	Recruitment underway	1 patient treated 1 patient awaiting treatment 4 patients waitlisted
Manufacturing	GMP compliant	12 out of 12 successful runs



# TOTAL GLOBAL MARKET SIZE

CHIMERIC THERAPEUTICS



CHIMERIC THERAPEUTICS.COM

<https://www.grandviewresearch.com/industry-analysis/pancreatic-cancer-treatment-market>  
<https://www.grandviewresearch.com/industry-analysis/stomach-cancer-gastric-cancer-market>  
<https://www.grandviewresearch.com/industry-analysis/colorectal-cancer-crc-drugs-therapeutic-market>



# SUMMARY

● ●  
**CHM CDH17**  
CHM 2101

11 patients treated, 1 awaiting treatment

12/12 manufacturing runs

Anti-tumour activity observed

No safety issues to date

No off-target effects

## FY26 Deliverables

Complete Dose level 2

Commence Dose level 3

Conclude Phase 1

Phase 2 readiness



# CHM CORE NK

Clinical Trial Update





# CHM CORE-NK 2 PHASE 1B TRIALS OPEN

Phase 1b clinical trials OPEN

CHM CORE-NK  
'OFF THE SHELF' NK

Technology from:

 **CASE WESTERN RESERVE UNIVERSITY**

PHASE 1B TRIAL OPEN	PHASE 1B TRIAL SUSPENDED
------------------------	-----------------------------

## OFF THE SHELF: ALLOGENEIC

NK cell expansion platform: **Universal Donor**

Positive Phase 1A Clinical Trial in AML

Two ongoing Phase 1B Clinical Trials in AML

**MDACC AML:** Cohort 1 cleared, moved to dose expansion for Cohort 2  
**FRONTLINE - A FIRST IN CELL THERAPY**  
Multiple Patient dosed; rapidly recruiting


Case Western AML: Trial suspended due to IL-2 Shortage



# AML PHASE 1B CLINICAL TRIAL OPEN

CHM CORE-NK + AZA + VEN in FRONTLINE AML

Clinical Trials.gov Identifier: NCT05834244



CORE NK CELLS

FDA REGISTERED CHEMOTHERAPY


FDA REGISTERED BLOOD CANCER DRUG

○ ●  
**CHM CORE NK**  
'OFF THE SHELF' NK



# CHM CORE-NK FRONTLINE PHASE 1 STUDY RESULTS

Four Completes Responses, 1 Partial Response



**Complete Response** means that all visible or measurable signs of cancer have disappeared after treatment  
**Partial Response** means the cancer has reduced by at least 50% but not entirely disappeared in response to treatment



# SUMMARY CHM CORE-NK

## CHM CORE-NK

'OFF THE SHELF' NK

Investigator Sponsored Trial – MD ANDERSON

Dose Escalation completed

First Line Dosing Underway – up to 20 patients

No safety issues to date

FY26 Deliverables

Complete dosing of 20 patients; subject to MD Anderson



# SUMMARY

## CHM CDH17

CHM 2101

11 patients treated  
12/12 manufacturing runs  
Tumour shrinkage observed 10  
No unexpected safety issues to date  
No off-target effects

## CHM CORE-NK

'OFF THE SHELF' NK

Investigator Sponsored Trial – MD ANDERSON  
Dose Escalation completed  
First Line Dosing Underway – 7 dosed up to 20 patients  
No safety issues to date



# CHIMERIC

PIONEERS IN CELL THERAPY

[investors@chimerictherapeutics.com](mailto:investors@chimerictherapeutics.com)



ASX:  
CHM